Navigation Links
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Date:9/10/2009

found that LEVADEX also was effective compared to placebo in treating migraine:

  • in patients with or without allodynia;
  • at any time during the migraine attack, regardless of how long patients had waited to treat a migraine;
  • that occurs in the early morning, also known as "morning migraine";
  • in severely disabled and non disabled patients, as defined by a HIT-6 score;
  • with severe as well as moderate intensity of baseline pain;
  • with severe intensity of pain, providing pain relief at 10 minutes; and
  • with and without nausea, vomiting and aura.

Additional LEVADEX data from the Phase 3 trial showed rapid and sustained efficacy in treating migraine with:

  • pain relief at 10 minutes (p=0.16) and time to pain relief at 30 minutes (p=0.03);
  • sustained pain relief from two to 24 hours in 44 percent of patients compared to 20 percent for placebo (p<0.0001);
  • sustained pain relief from two to 48 hours in 36 percent of patients compared to 17 percent for placebo (p<0.0001, unadjusted for multiplicity); and
  • sustained pain free from two to 24 hours in 23 percent of patients compared to 7 percent for placebo, and from two to 48 hours in 18 percent of patients compared to 6 percent for placebo (p<0.0001 for both timepoints, unadjusted for multiplicity).

There were no drug-related serious adverse events reported in the trial. LEVADEX was well tolerated, with the most common adverse event reported being medication aftertaste at six percent, with two percent of patients receiving placebo also reporting medication aftertaste. The next most common adverse event was nausea at five percent, compared with two percent for placebo. Symptoms or sensitivities typically associated with commonly used triptan migraine treatments, such as ch
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... CLAREMONT, Calif., Dec. 9 The U.S. Food and ... orphan drug workshop series--an opportunity for biotechnology companies, pharmaceutical ... days creating applications for orphan status designation, under the ... Development (OOPD). The first workshop is planned for Feb. ...
... BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced ... Company,s Board of Directors. Dr. Sanders brings to BioCryst ... professor of medicine. , "We are pleased to ... P. Horovitz, Ph.D., Chairman of the Board of BioCryst Pharmaceuticals. ...
Cached Medicine Technology:FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4
(Date:7/12/2014)... (PRWEB) July 12, 2014 The report, ... Alkyd Resins) Market by Application & Geography – Trends ... market with analysis and forecasting of market volume and ... of the derivatives separately. The market of phthalic anhydride ... in 2013 to $8,415.89 million by 2018, with a ...
(Date:7/12/2014)... 2014 In this cognitive ... assessment and training’ is defined as solution ... or enhance cognitive functions. These solutions are ... dementia screening, clinical trials, driver’s safety, rehabilitation, ... assessment, brain training, and employers’ assessment and ...
(Date:7/12/2014)... The fastest-growing mobile technology is LTE (Long Term Evolution). ... continues to grow due to the rapid evolution of ... data traffic, which is a major driver for the ... Measurement equipment comply with industry standards, and services which ... Market is estimated to grown from $3.75 billion in ...
(Date:7/12/2014)... 2014 (HealthDay News) -- If you make exercise fun, you,ll ... one experiment, 56 adults were led on a 1.4-mile walk ... or a scenic walk. The participants were given lunch after ... exercise outing ate 35 percent more chocolate pudding for dessert ... In another experiment, 46 adults were given mid-afternoon snacks ...
(Date:7/12/2014)... 2014 Sean Francis, owner of the Kawartha Lakes ... to his clients. He’s also known for his support of local ... way to combine the two and is excited to announce that ... Boys and Girls Club. , The funds are the result of ... 23rd. Francis sent out emails and asked his clients to put ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3
... Calif., Nov. 19 ,Natrol, Inc, (Nasdaq: NTOL ... nutritional products, and Gener8Xion Entertainment, Inc.,(OTC Bulletin Board: ... a letter of intent for a strategic,alliance to ... intends to,exclusively license the "Living Pure" brand to ...
... as World,s Leading Thoroughbred ... Radiography Review, SANTA CLARA, Calif., Nov. 19 ... doors to the,annual September Yearling Sale, the medical repository ... medical images. Beginning with 12,review workstations from Eklin Medical ...
... HCA Study Reveals Qualities of High-Performing Organizations, ... from The Beryl,Institute, titled "High Performing Organizations: Culture ... satisfaction are highly,correlated with outstanding clinical care and ... bottom line. Using the,results of a study done ...
... Nov. 19 Boston Scientific,Corporation (NYSE: BSX ... been,reached to settle claims associated with a series ... and 2006. Boston Scientific acquired,Guidant last year. This ... July 2007 to cover additional unanticipated claims. ...
... - ... 8,550 Patient Plaintiffs -, MINNEAPOLIS, Nov. 19 ... Medical Device Litigation,announced today that an amended settlement agreement ... asserted claims against Guidant,Corporation, Boston Scientific Corporation and other ...
... Flagship Global Health,Inc. (OTC Bulletin Board: FGHH), a ... priority access to, the world,s leading,doctors has added ... and services field to lead its Marketing and ... marketing and sales at Flagship,Global Health and, in ...
Cached Medicine News:Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 2Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 3Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 4Health News:Keeneland Scales Eklin Digital Repository(TM) to 32 Medical Image Review Workstations 2Health News:Keeneland Scales Eklin Digital Repository(TM) to 32 Medical Image Review Workstations 3Health News:Boston Scientific Announces Amended Agreement to Settle Product Lawsuits 2Health News:Boston Scientific Announces Amended Agreement to Settle Product Lawsuits 3Health News:Plaintiffs Obtain $240 Million Amended Settlement In Guidant Defibrillators Products Liability Litigation 2Health News:Flagship Global Health Hires Health Care Veteran Larsen to Head Marketing and Sales 2
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
Medicine Products: